Avanza Auto 1 vs UBS Lux Equity Fund Biotech USD

Avanza Auto 1 vs UBS Lux Equity Fund Biotech USD

1. Avanza Auto 1

  • Security

    Avanza Auto 1

  • Fee

    0.35%

  • ISIN

    SE0009779655

  • Holdings

    15

2. UBS Lux Equity Fund Biotech USD

  • Security

    UBS Lux Equity Fund Biotech USD P-acc

  • Fee

    2.25%

  • ISIN

    LU0069152568

  • Holdings

    10

Fund Holdings

We have information about 18 holdings in Avanza Auto 1, where the largest holding is AMF Räntefond Mix (14.72), followed by Danske Invest Sverige Kort Ränta SA (14.51) and Swedbank Robur Räntefond Kort A (14.5). In comparison with UBS Lux Equity Fund Biotech USD, we have 14 holdings where Regeneron Pharmaceuticals is the largest holding (10.04), followed by Vertex (9.9) and Moderna (9.21).

All Holdings

Here we compare the holdings in Avanza Auto 1 and UBS Lux Equity Fund Biotech USD.

Avanza Auto 1 UBS Lux Equity Fund Biotech USD
1. AMF Räntefond Mix
Sweden
14.72 %
1. Regeneron Pharmaceuticals Inc
10.04 %
2. Danske Invest Sverige Kort Ränta SA
Luxembourg
14.51 %
2. Vertex Pharmaceuticals Inc
9.9 %
3. Swedbank Robur Räntefond Kort A
Sweden
14.5 %
3. Moderna Inc
9.21 %
4. Amundi Global AGG SRI UCITS I13HSK C
Luxembourg
13.47 %
4. Alnylam Pharmaceuticals Inc
6.54 %
5. Captor Aster Global Credit A
Sweden
8.88 %
5. AbbVie Inc
USA
5.52 %
6. Captor Aster Global Credit Short-Term A
Sweden
8.71 %
6. Gilead Sciences Inc
USA
4.66 %
7. Storebrand Global Företagsobligation A SEK
Sweden
4.37 %
7. Amgen Inc
4.32 %
8. Storebrand Global Plus A SEK
Sweden
4.22 %
8. BioNTech SE
4.13 %
9. Avanza Global
Sweden
4.11 %
9. Karuna Therapeutics Inc
3.75 %
10. Öhman Marknad Global A
Sweden
4.08 %
10. Royalty Pharma Plc
3.28 %
11. Handelsbanken Developed Markets Index Criteria A1 SEK
Sweden
4.07 %
-
12. Avanza Sverige
Sweden
2.01 %
-
13. Handelsbanken Amerika Små Tema A1 SEK
Sweden
0.55 %
-
14. Storebrand Emerging Markets Plus A SEK
Sweden
0.21 %
-
15. Öhman Emerging Markets A
Sweden
0.21 %
-

The list of fund holdings was last updated on April 17, 2025.